Hormone replacement therapy after hysterectomy is one of the most important and most misunderstood topics in women's health. Decades of media coverage shaped by a single flawed study left a generation of women afraid of HRT — and many healthcare providers equally cautious. The science has moved on considerably since then, and the current picture is meaningfully different. This blog explores what HRT is, what we now know about its risks and benefits specifically after hysterectomy, and the questions worth bringing to your next medical appointment.
What HRT is and how it works
Hormone replacement therapy replaces the hormones — primarily oestrogen, and sometimes progesterone and testosterone — that the body is no longer producing in adequate quantities. After menopause, whether natural or surgical, declining oestrogen levels produce a wide range of symptoms and long-term health risks. HRT addresses both the symptoms and, depending on the type and timing, the underlying physiological consequences of oestrogen deficiency.
HRT comes in many forms: patches, gels, sprays, and oral tablets for systemic oestrogen; vaginal creams, pessaries, and rings for local oestrogen; and implants or topical preparations for testosterone. The right form depends on individual preference, medical history, absorption, and which symptoms need addressing. There is no single 'standard' prescription — HRT should be individualised.
Why HRT after hysterectomy is different
This distinction is critical and frequently misunderstood. Women who have a uterus and take systemic HRT require both oestrogen and a progestogen (progesterone or a synthetic equivalent). This is because oestrogen alone, when the uterus is present, stimulates the uterine lining and increases the risk of endometrial cancer. The progestogen protects against this.
Women who have had a hysterectomy no longer have a uterus — and therefore do not need progestogen for uterine protection. This means they can take oestrogen-only HRT. This matters because much of the concern around HRT and breast cancer risk has been associated specifically with combined (oestrogen plus progestogen) HRT, not with oestrogen-only preparations. The risk profile of oestrogen-only HRT is considered more favourable — and for women who have had a hysterectomy, particularly those who have entered surgical menopause before the natural age, the benefits of oestrogen-only HRT are well established and generally considered to outweigh the risks.
The history of HRT fear — and what the science actually shows now
In 2002, the Women's Health Initiative study published results that prompted widespread withdrawal from HRT by both patients and prescribers. Headlines reported increased risks of breast cancer, heart disease, and stroke. What those headlines failed to capture was the complexity: the study used older women (average age 63), used a specific oral combined HRT preparation, and the risks were reported in relative rather than absolute terms — making them sound much larger than they were in practice.
Subsequent research — including re-analysis of the same data and newer studies using different formulations and populations — has painted a substantially more nuanced picture. Oestrogen-only HRT shows no significant increase in breast cancer risk and may actually be associated with a slight reduction. Transdermal oestrogen (patches, gels) does not carry the same blood clot risk as oral oestrogen. And the timing matters: starting HRT close to the onset of menopause, rather than years later, is associated with greater cardiovascular benefit and reduced cognitive risk — this is the 'window of opportunity' concept now well-established in menopause medicine.
For women who have had bilateral oophorectomy before the natural age of menopause, the calculus is particularly clear: the health risks of untreated oestrogen deficiency — to bones, heart, and brain — are significant and well documented, and appropriate HRT substantially mitigates them.
Who should consider HRT after hysterectomy
Women who have entered surgical menopause before the natural age of approximately 51 are the strongest candidates for HRT, and current guidelines support offering it routinely to this group unless there is a specific contraindication.
Women who have retained their ovaries but are experiencing significant menopausal symptoms — whether due to ovarian disruption from surgery or natural perimenopause — may also benefit from HRT once the hormonal picture has been assessed.
Women who are experiencing significant quality-of-life impairment from menopausal symptoms — hot flushes that disrupt sleep, vaginal dryness that affects sexual health, mood changes that affect daily function, cognitive changes that affect work — are candidates for HRT regardless of age, provided contraindications are considered.
Women who have had certain cancers — particularly hormone-sensitive breast cancer — require specialist guidance before starting HRT, as recommendations vary by cancer type, grade, and treatment received. This is a conversation to have with an oncologist and a menopause specialist together.
Testosterone after hysterectomy with bilateral oophorectomy
Testosterone replacement for women after surgical menopause is not yet universally offered, but it has good evidence for improving libido, energy, motivation, and cognitive function. Testosterone is produced in meaningful quantities by the ovaries, and its loss in bilateral oophorectomy is significant. If you have had both ovaries removed and are experiencing low libido, fatigue, reduced motivation, or cognitive flatness, testosterone is worth discussing with your prescribing doctor specifically. It is not automatically included in HRT regimens and often needs to be asked about.
Local vaginal oestrogen: the most underused tool
Local vaginal oestrogen — delivered as a cream, pessary, tablet, or ring directly to the vaginal tissue — treats vaginal atrophy (thinning, dryness, and reduced elasticity of vaginal tissue) and associated urinary symptoms. It is highly effective, has minimal systemic absorption, and is generally considered safe even for women who cannot take systemic HRT. It is not a substitute for systemic HRT in addressing hot flushes or bone health, but for the specific symptoms of genitourinary menopause syndrome — vaginal dryness, painful sex, urinary frequency and urgency — it is often the most directly effective treatment available.
Many women are not aware that local vaginal oestrogen exists as a separate option, or that it can be used alongside systemic HRT. And many women who are using systemic HRT still develop vaginal symptoms that need local treatment in addition. Both conversations are worth having with your GP or prescribing specialist.
Questions worth bringing to your doctor
Am I a candidate for HRT given my surgical history and current health? What type of HRT would be most appropriate for me — oestrogen only, and in what form? Should testosterone be part of my hormonal support? Should I be using local vaginal oestrogen regardless of whether I take systemic HRT? How long should I take HRT, and how will we review this over time? What are the specific risks in my individual case, and how do they compare to the benefits? If I cannot take HRT, what are the most effective alternatives for my specific symptoms?
If your GP is not comfortable answering these questions in depth, or if you feel your concerns are not being adequately addressed, a referral to a menopause specialist is a reasonable and appropriate request. You are entitled to fully informed decision-making about your own hormonal health.
Ready to feel supported in your recovery?
HRT is one piece of a larger recovery picture, and navigating it well requires good information and good support. The Complete Comeback Program helps you understand your hormonal options, prepare for conversations with your medical team, and make informed decisions that support both your recovery and your long-term health. You deserve clarity, not confusion — and you deserve a team who can help you get there.